Nasopharyngeal cancer in China
Toripalimab, a Chinese PD-1 antibody approved in China for nasopharyngeal carcinoma, became the first FDA-approved NPC drug in October 2023. Chemoradiotherapy is standard at Chinese cancer hospitals, and proton or carbon ion therapy is offered at a few centers. Access is through oncology departments or trials.
VerifiedLast verified
Treatments available
Hospitals with documented programs
Informational listings from cited public sources, not recommendations.
ShanghaiFudan University Shanghai Cancer Center复旦大学附属肿瘤医院International deptReported
ShanghaiShanghai Proton and Heavy Ion Center上海市质子重离子医院International deptJCIVerified
HangzhouZhejiang Cancer Hospital (Cancer Hospital of the University of Chinese Academy of Sciences)浙江省肿瘤医院（中国科学院大学附属肿瘤医院）No public intl deptVerified
GuangzhouSun Yat-sen University Cancer Center中山大学肿瘤防治中心International deptVerified
Clinical trials
151studies listed as recruiting with a site in China on ClinicalTrials.gov, as of 2026-10-26. See the list
We link trials only; enrollment decisions belong to trial teams. Since May 2026, charging patients to join clinical research is prohibited in China, as reported by AFP.
Frequently asked
Is toripalimab approved in both China and the US?
Yes. The FDA approved it on October 27, 2023 for first-line metastatic or recurrent locally advanced NPC with chemotherapy and as a single agent after platinum chemotherapy. FDA's review notes it already had China authorization for NPC.
[1] U.S. FDA[2] U.S. FDAHow many NPC trials recruit in China?
ClinicalTrials.gov listed 151 recruiting studies with a China site for nasopharyngeal carcinoma on 2026-10-26.
[1] ClinicalTrials.gov (…Sources
- FDA approves toripalimab-tpzi for nasopharyngeal carcinoma
“On October 27, 2023, the Food and Drug Administration approved toripalimab-tpzi (LOQTORZI) with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma.”
- LOQTORZI multidiscipline review (BLA 761240)
“Toripalimab has marketing authorization in China for the treatment of melanoma, nasopharyngeal carcinoma (NPC), urothelial carcinoma and non-small cell lung cancer (NSCLC).”
- Particle therapy facilities in clinical operation
“Lists SPHIC Shanghai (proton and carbon ion, from 2014/2015), WPTC Wanjie Zibo (proton, 2004) and the Wuwei Heavy Ion Therapy Center (carbon ion).”
Information only. Not medical advice, diagnosis or a treatment recommendation. Talk to your doctor. In an emergency, call your local emergency number.